Skip to main content
SpringerLink
Log in

The Global Epidemic of Metabolic Fatty Liver Disease

  • Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The objective of this manuscript is to examine the current literature on the epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD), its correlation with cardiovascular disease (CVD) outcomes, as well as to evaluate the update in nomenclature from non-alcoholic liver disease (NAFLD).

Recent Findings

The update of diagnostic criteria from NAFLD to MASLD reduces the stigma associated with alcohol consumption and poor health choices. It also shines a light on the crucial role of cardiometabolic risk factors in disease pathophysiology. The incidence and prevalence of MASLD are projected to increase significantly in the future as the population burden of cardiometabolic risk factors rises. MASLD is also a potent risk factor for developing CVD that should be tackled by using a multi-disciplinary team with a holistic approach.

Summary

As the new nomenclature for metabolic liver disease is adopted on a global scale, more research is needed to investigate the applicability of findings from previous trials focusing on NAFLD. It is anticipated that the epidemic of MASLD will continue to increase globally, hence the urgent need for therapeutic approaches to reverse this trend.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

No datasets were generated or analysed during the current study.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis (Hoboken). 2021;17(5):365–70. https://doi.org/10.1002/cld.1061.

    Article  PubMed  Google Scholar 

  2. •• Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023. https://doi.org/10.1097/hep.0000000000000520. This study proposed the change in nomenclature from NAFLD to MASLD, following a modified Delphi consensus from an international committee of experts.

  3. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–61. https://doi.org/10.1016/s2468-1253(22)00165-0.

    Article  PubMed  Google Scholar 

  4. Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. https://doi.org/10.1016/j.jhep.2019.06.021.

    Article  PubMed  Google Scholar 

  5. Puri P, Fuchs M. Population management of nonalcoholic fatty liver disease. Fed Pract. 2019;36(2):72–82.

    PubMed  PubMed Central  Google Scholar 

  6. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–8.

    CAS  PubMed  Google Scholar 

  7. Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312.

    Article  CAS  PubMed  Google Scholar 

  8. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9. https://doi.org/10.1016/j.jhep.2020.03.039.

    Article  PubMed  Google Scholar 

  9. García-Compeán D, Jiménez-Rodríguez AR. NAFLD VS MAFLD. The evidence-based debate has come. Time to change? https://doi.org/10.1016/j.aohep.2022.100765. Annals Hepatol. 2022. https://doi.org/10.1016/j.aohep.2022.100765

  10. Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl):S17-s31. https://doi.org/10.3350/cmh.2022.0367.

    Article  PubMed  Google Scholar 

  11. De A, Ahmad N, Mehta M, Singh P, Duseja A. NAFLD vs MAFLD – it is not the name but the disease that decides the outcome in fatty liver. J Hepatol. 2022;76(2):475–7. https://doi.org/10.1016/j.jhep.2021.09.002.

    Article  PubMed  Google Scholar 

  12. WHO. Cardiovascular diseases (CVDs). Updated 11 June 2021. Accessed 9 Oct 2023, 2023. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

  13. Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921–37. https://doi.org/10.1007/s00392-020-01709-7.

    Article  PubMed  Google Scholar 

  14. Federation WH. Deaths from cardiovascular disease surged 60% globally over the last 30 years: report. Updated 20 May 2023. Accessed 9 Oct 2023, https://world-heart-federation.org/news/deaths-from-cardiovascular-disease-surged-60-globally-over-the-last-30-years-report/#:~:text=Search%20for%3A%20Search-,Deaths%20from%20cardiovascular%20disease%20surged%2060%25%20globally,the%20last%2030%20years%3A%20Report&text=GENEVA%2C%2020%20May%202023%20%E2%80%93%20Deaths,World%20Heart%20Federation%20(WHF)

  15. Li H, Guo M, An Z, Meng J, Jiang J, Song J, et al. Prevalence and risk factors of metabolic associated fatty liver disease in Xinxiang, China. Int J Environ Res Public Health. 2020;17(6). https://doi.org/10.3390/ijerph17061818. https://mdpi-res.com/d_attachment/ijerph/ijerph-17-01818/article_deploy/ijerph-17-01818.pdf?version=1583935402

  16. Zhang D, Zhang L, Chen S, Chen R, Zhang X, Bai F. Prevalence and risk factors of metabolic-associated fatty liver disease among hospital staff. Diabetes, Metabolic Syndrome and Obesity. 2023;16:1221–34. https://doi.org/10.2147/dmso.s407657.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Chen Y-L, Li H, Li S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21(1). https://doi.org/10.1186/s12876-021-01782-w

  18. Guan L, Zhang X, Tian H, et al. Prevalence and risk factors of metabolic-associated fatty liver disease during 2014–2018 from three cities of Liaoning Province: an epidemiological survey. BMJ Open. 2022;12(2): e047588. https://doi.org/10.1136/bmjopen-2020-047588.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yuan Q, Wang H, Gao P, Chen W, Lv M, Bai S, et al. Prevalence and risk factors of metabolic-associated fatty liver disease among 73,566 individuals in Beijing, China. Int J Environ Res Public Health. Feb 13 2022;19(4). https://doi.org/10.3390/ijerph19042096

  20. Rezaianzadeh A, Moftakhar L, Seif M, Johari MG, Hosseini SV, Dehghani SS. Incidence and risk factors of cardiovascular disease among population aged 40–70 years: a population-based cohort study in the South of Iran. Trop Med Health. 2023/06/12 2023;51(1):35. https://doi.org/10.1186/s41182-023-00527-7

  21. Arsyad DS, Westerink J, Cramer MJ, et al. Modifiable risk factors in adults with and without prior cardiovascular disease: findings from the Indonesian National Basic Health Research. BMC Public Health. 2022;22(1):660. https://doi.org/10.1186/s12889-022-13104-0

  22. Tran DT, Lekhak N, Gutierrez K, Moonie S. Risk factors associated with cardiovascular disease among adult Nevadans. PLoS ONE. 2021;16(2): e0247105. https://doi.org/10.1371/journal.pone.0247105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Maharani A, Sujarwoto, Praveen D, Oceandy D, Tampubolon G, Patel A. Cardiovascular disease risk factor prevalence and estimated 10-year cardiovascular risk scores in Indonesia: the SMARThealth extend study. PLOS ONE. 2019;14(4):e0215219. https://doi.org/10.1371/journal.pone.0215219

  24. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology. 2018;67(1):328–57. https://doi.org/10.1002/hep.29367.

    Article  PubMed  Google Scholar 

  25. Liu Q, Zhao G, Li Q, Wu W, Zhang Y, Bian H. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study. BMC Gastroenterol. 2022/11/19 2022;22(1):471. https://doi.org/10.1186/s12876-022-02576-4

  26. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. https://doi.org/10.1016/j.jhep.2020.03.039

  27. Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082–9. https://doi.org/10.1111/liv.14548.

    Article  PubMed  Google Scholar 

  28. Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194–8. https://doi.org/10.1002/hep.31420.

    Article  PubMed  Google Scholar 

  29. Huang J, Kumar R, Wang M, Zhu Y, Lin S. MAFLD criteria overlooks a number of patients with severe steatosis: is it clinically relevant? J Hepatol. 2020;73(5):1265–7. https://doi.org/10.1016/j.jhep.2020.06.016.

    Article  PubMed  Google Scholar 

  30. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91(6):319–27. https://doi.org/10.1097/MD.0b013e3182779d49.

    Article  PubMed  Google Scholar 

  31. Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: implications for clinical practice and research activity. World J Hepatol. 2021;13(11):1584–610. https://doi.org/10.4254/wjh.v13.i11.1584.

    Article  PubMed  PubMed Central  Google Scholar 

  32. • Lim GEH, Tang A, Ng CH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023/03/01/ 2023;21(3):619–629.e7. https://doi.org/10.1016/j.cgh.2021.11.038. This meta-analysis shows how patients had a significantly higher odds of being diagnosed with MAFLD compared to NAFLD, showcasing the greater prevalence of MAFLD over NAFLD.

  33. Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD, MAFLD, MASLD and pure-MASLD characteristics and mortality outcomes in United States adults. medRxiv. 2023:2023.09.26.23296130. https://doi.org/10.1101/2023.09.26.23296130

  34. Chan KE, Ng CH, Fu CE, et al. The spectrum and impact of metabolic dysfunction in MAFLD: a longitudinal cohort analysis of 32,683 overweight and obese individuals. Clin Gastroenterol Hepatol. 2023;21(10):2560-2569.e15. https://doi.org/10.1016/j.cgh.2022.09.028.

    Article  CAS  PubMed  Google Scholar 

  35. Chun HS, Lee JS, Lee HW, et al. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than nonalcoholic fatty liver disease. Hepatol. 2022;76 (Supplement 1):S789. Annual meeting of the American Association for the Study of Liver Diseases, AASLD 2022. Virtual. https://doi.org/10.1002/hep.32697

  36. Lee H, Lee Y-H, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(10):2138–2147.e10. Comment in: Clin Gastroenterol Hepatol. 2021 Oct;19(10):2025–2028 PMID: 33610759 [https://www.ncbi.nlm.nih.gov/pubmed/33610759]. https://doi.org/10.1016/j.cgh.2020.12.022

  37. Lei F, Qin J-J, Song X, et al. The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China. Front Endocrinol. 2022;13:1007171. https://doi.org/10.3389/fendo.2022.1007171.

    Article  Google Scholar 

  38. Liu Z, Suo C, Shi O, et al. The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2022;20(4):e855–75. https://doi.org/10.1016/j.cgh.2020.12.033.

    Article  CAS  PubMed  Google Scholar 

  39. Park H, Yoon EL, Kim M, Cho S, Nah E-H, Jun DW. Nomenclature dilemma of metabolic associated fatty liver disease (MAFLD): considerable proportions of MAFLD are metabolic healthy. Clin Gastroenterol Hepatol. 2023;21(4):1041–1049.e3. Comment in: Clin Gastroenterol Hepatol. 2023;21(3):857–858 PMID: 35643417. [https://www.ncbi.nlm.nih.gov/pubmed/35643417] Comment in: Clin Gastroenterol Hepatol. 2023 Apr;21(4):1114–1115 PMID: 35700885. https://www.ncbi.nlm.nih.gov/pubmed/35700885. https://doi.org/10.1016/j.cgh.2022.04.012

  40. Thrift AP, Nguyen TH, Pham C, et al. The prevalence and determinants of NAFLD and MAFLD and their severity in the VA primary care setting. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023;21(5):1252-1260.e5. https://doi.org/10.1016/j.cgh.2022.05.046.

    Article  PubMed  Google Scholar 

  41. Zeng J, Qin L, Jin Q, et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: a community-based study. Hepatobiliary & pancreatic diseases international : HBPD INT. 2022;21(2):154–161. Comment in: Hepatobiliary Pancreat Dis Int. 2022 Apr;21(2):103–105 PMID: 35125337. https://www.ncbi.nlm.nih.gov/pubmed/35125337. https://doi.org/10.1016/j.hbpd.2022.01.006

  42. Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from global burden of disease 2009–2019. J Hepatol. 2021;75(4):795–809. https://doi.org/10.1016/j.jhep.2021.05.022

  43. Wang J, He W, Tsai P-J, Chen P-H, Ye M, Guo J, et al. Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease. Lipids Health Dis. 2020;19(1):72. https://doi.org/10.1186/s12944-020-01210-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol. 2015;8(1):1–9. https://doi.org/10.1007/s12328-014-0548-5.

    Article  PubMed  Google Scholar 

  45. Bae SDW, George J, Qiao L. From MAFLD to hepatocellular carcinoma and everything in between. Chin Med J (Engl). 2022;135(5):547–56. https://doi.org/10.1097/cm9.0000000000002089.

    Article  CAS  PubMed  Google Scholar 

  46. Yu J. Obesity, fatty liver and liver cancer. vol 1061. Advances in experimental medicine and biology. Springer Singapore; 2018:157.

  47. Chen X, Chen S, Pang J, Tang Y, Ling W. Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality? J Hepatol. 2021;75(4):987–989. https://doi.org/10.1016/j.jhep.2021.06.013

  48. Park H, Yoon EL, Kim M, Cho S, Nah E-H, Jun DW. Nomenclature dilemma of metabolic associated fatty liver disease (MAFLD): considerable proportions of MAFLD are metabolic healthy. Clin Gastroenterol Hepatol. 2023;21(4):1041–1049.e3. https://doi.org/10.1016/j.cgh.2022.04.012

  49. Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and cardiovascular diseases: epidemiological, mechanistic and therapeutic considerations. J Clin Med. Jan 26 2021;10(3). https://doi.org/10.3390/jcm10030467

  50. Lim S, Meigs JB. Links between ectopic fat and vascular disease in humans. Arterioscler Thromb Vasc Biol. 2014;34(9):1820–6. https://doi.org/10.1161/ATVBAHA.114.303035.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012;10(6):646–50. https://doi.org/10.1016/j.cgh.2011.12.039.

    Article  PubMed  Google Scholar 

  52. Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016;6:33386. https://doi.org/10.1038/srep33386

  53. Zhou X-D, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773–791. https://doi.org/10.1007/s12072-023-10543-8

  54. Clinic M. Metabolic syndrome. Updated 6 May 2021. Accessed 9 Oct 2023. https://www.mayoclinic.org/diseases-conditions/metabolic-syndrome/diagnosis-treatment/drc-20351921

  55. Shaw DI, Hall WL, Williams CM. Metabolic syndrome: what is it and what are the implications? Proceedings of the Nutrition Society. 2005;64(3):349–57. https://doi.org/10.1079/PNS2005442.

    Article  CAS  PubMed  Google Scholar 

  56. Solomon A, Negrea MO, Cipăian CR, et al. Interactions between metabolic syndrome, MASLD, and arterial stiffening: a single-center cross-sectional study. Healthcare. 2023;11(19):2696. https://doi.org/10.3390/healthcare11192696.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. Gerontology. 2009;55(6):607–13. https://doi.org/10.1159/000235677.

    Article  CAS  PubMed  Google Scholar 

  58. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–528. https://doi.org/10.1161/cir.0000000000000659.

    Article  PubMed  Google Scholar 

  59. Amer OE, Sabico S, Khattak MNK, et al. Increasing prevalence of pediatric metabolic syndrome and its components among Arab youth: a time-series study from 2010–2019. Children (Basel). 2021;8(12). https://doi.org/10.3390/children8121129

  60. Anand VV, Zhe ELC, Chin YH, et al. Socioeconomic deprivation and prognostic outcomes in acute coronary syndrome: a meta-analysis using multidimensional socioeconomic status indices. Int J Cardiol. 2023;383:140–50. https://doi.org/10.1016/j.ijcard.2023.04.042.

    Article  PubMed  Google Scholar 

  61. Das M. WHO urges immediate action to tackle non-communicable diseases. Lancet Oncol. 2022;23(11):1361. https://doi.org/10.1016/S1470-2045(22)00606-4.

    Article  PubMed  Google Scholar 

  62. Eslam M, Sarin SK, Wong VW-S, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919. https://doi.org/10.1007/s12072-020-10094-2

  63. Marx N, Federici M, Schütt K, et al. ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023. https://doi.org/10.1093/eurheartj/ehad192

  64. Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–85. https://doi.org/10.1161/ATV.0000000000000153.

    Article  CAS  PubMed  Google Scholar 

  65. Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol. 2014;20(36):12956–80. https://doi.org/10.3748/wjg.v20.i36.12956.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Machado MV. Aerobic exercise in the management of metabolic dysfunction associated fatty liver disease. Diabetes Metab Syndr Obes. 2021;14(null):3627–3645. https://doi.org/10.2147/DMSO.S304357

  67. van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The effects of physical exercise on fatty liver disease. Gene Expr. 2018;18(2):89–101. https://doi.org/10.3727/105221617x15124844266408.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Golabi P, Locklear CT, Austin P, Afdhal S, Byrns M, Gerber L, et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: systematic review. World J Gastroenterol. 2016;22(27):6318–27. https://doi.org/10.3748/wjg.v22.i27.6318.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Tsompanaki E, Thanapirom K, Papatheodoridi M, Parikh P, Chotai de Lima Y, Tsochatzis EA. Systematic review and meta-analysis: the role of diet in the development of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21(6):1462–1474.e24. https://doi.org/10.1016/j.cgh.2021.11.026

  70. Stewart KE, Haller DL, Sargeant C, Levenson JL, Puri P, Sanyal AJ. Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. Liver Int. 2015;35(3):936–43. https://doi.org/10.1111/liv.12483.

    Article  PubMed  Google Scholar 

  71. Wing RR, Phelan S. Long-term weight loss maintenance23. Am J Clin Nutr. 2005;82(1):222S-225S. https://doi.org/10.1093/ajcn/82.1.222S

  72. Anand VV, Zhe ELC, Chin YH, et al. Barriers and facilitators to engagement with a weight management intervention in Asian patients with overweight or obesity: a systematic review. Endocr Pract. 2023;29(5):398–407. https://doi.org/10.1016/j.eprac.2022.10.006.

    Article  PubMed  Google Scholar 

  73. Foster D, Sanchez-Collins S, Cheskin LJ. Multidisciplinary team-based obesity treatment in patients with diabetes: current practices and the state of the science. Diabetes Spectr. 2017;30(4):244–9. https://doi.org/10.2337/ds17-0045.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. https://doi.org/10.1056/NEJMoa1607141.

    Article  CAS  PubMed  Google Scholar 

  76. ACC. Semaglutide reduces risk of MACE in adults with overweight or obesity. Updated 10 Aug 2023. Accessed 9 Oct 2023, https://www.acc.org/Latest-in-Cardiology/Articles/2023/08/10/14/29/SELECT-Semaglutide-Reduces-Risk-of-MACE-in-Adults-With-Overweight-or-Obesity#:~:text=Subcutaneous%20once%2Dweekly%20semaglutide%202.4,8%20press%20release.

  77. Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2019;394(10213):2012–24. https://doi.org/10.1016/s0140-6736(19)32517-6.

    Article  CAS  Google Scholar 

  78. Powell NR, Liang T, Ipe J, et al. Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease. Nature Commun. 2023;14(1):1474. https://doi.org/10.1038/s41467-023-37209-1

  79. Wen W, Li H, Wang C, et al. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: a meta-analysis. Front Endocrinol (Lausanne). 2022;13: 934225. https://doi.org/10.3389/fendo.2022.934225.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Ethan C. Z. Lee and Vickram V. Anand are contributed equally as co-first authors.

Authors and Affiliations

  1. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore

    Ethan C. Z. Lee & Vickram V. Anand

  2. Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA

    Alex C. Razavi

  3. VCU Health Pauley Heart Center, Virginia Commonwealth University School of Medicine, 1200 East Broad Street, PO Box 980036, Richmond, VA, 23298, USA

    Pamela L. Alebna & Anurag Mehta

  4. Division of Gastroenterology & Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore

    Mark D. Muthiah

  5. Stravitz-Sanyal Institute of Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond, VA, USA

    Mohammad S. Siddiqui

  6. Department of Cardiology, National University Heart Centre, National University Health System, Singapore, Singapore

    Nicholas W. S. Chew

Authors
  1. Ethan C. Z. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vickram V. Anand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alex C. Razavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pamela L. Alebna
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark D. Muthiah
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohammad S. Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nicholas W. S. Chew
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anurag Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

E.L.C.Z and V.V.A wrote the main manuscript text and prepared the tables 1-2 A.M supervised the manuscript All authors reviewed the manuscript

Corresponding author

Correspondence to Anurag Mehta.

Ethics declarations

Conflict of Interests

The authors declare no conflict of interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (JPEG 4631 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, E.C.Z., Anand, V.V., Razavi, A.C. et al. The Global Epidemic of Metabolic Fatty Liver Disease. Curr Cardiol Rep 26, 199–210 (2024). https://doi.org/10.1007/s11886-024-02025-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-024-02025-6

Keywords

Search

Navigation